Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Partnerships 17
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Licensing Agreements 24
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Equity Offering 30
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc – Key Competitors 32
Cumberland Pharmaceuticals Inc – Key Employees 33
Cumberland Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter 35
Aug 08, 2017: Cumberland Pharmaceuticals Reports Double Digit Revenue Growth for the Fourth Consecutive Quarter 37
May 15, 2017: Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017 39
Mar 07, 2017: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results 41
Nov 01, 2016: Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results 43
Aug 02, 2016: Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results 45
May 10, 2016: Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results 47
Mar 03, 2016: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results 49
Corporate Communications 50
Jan 16, 2017: Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors 50
Jun 10, 2016: Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors 51
Product Approvals 52
Apr 27, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Vasculan For Systemic Sclerosis 52
Clinical Trials 53
Sep 14, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Portaban For Portal Hypertension 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc, Key Competitors 32
Cumberland Pharmaceuticals Inc, Key Employees 33
Cumberland Pharmaceuticals Inc, Subsidiaries 34